Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Lexeo Therapeutics, Inc. Common Stock (LXEO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: LXEO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $17.71
1 Year Target Price $17.71
| 4 | Strong Buy |
| 3 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -38.84% | Avg. Invested days 22 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 247.78M USD | Price to earnings Ratio - | 1Y Target Price 17.71 |
Price to earnings Ratio - | 1Y Target Price 17.71 | ||
Volume (30-day avg) 7 | Beta - | 52 Weeks Range 1.45 - 15.31 | Updated Date 07/11/2025 |
52 Weeks Range 1.45 - 15.31 | Updated Date 07/11/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.31 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -42.89% | Return on Equity (TTM) -80.65% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 157345311 | Price to Sales(TTM) - |
Enterprise Value 157345311 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 416.34 | Enterprise Value to EBITDA -6.02 | Shares Outstanding 53982000 | Shares Floating 24090533 |
Shares Outstanding 53982000 | Shares Floating 24090533 | ||
Percent Insiders 0.75 | Percent Institutions 121.11 |
Upturn AI SWOT
Lexeo Therapeutics, Inc. Common Stock
Company Overview
History and Background
Lexeo Therapeutics is a clinical-stage gene therapy company focused on developing treatments for genetically defined cardiovascular and central nervous system diseases. Founded in 2014 and headquartered in New York, NY, the company went public in October 2023 via IPO.
Core Business Areas
- Cardiovascular Disease: Developing gene therapies for genetic forms of cardiovascular disease, including LX2006 for Fabry disease cardiomyopathy.
- Central Nervous System (CNS) Diseases: Developing gene therapies for CNS diseases, including Alzheimer's disease and other neurodegenerative disorders.
Leadership and Structure
Dr. R. Nolan Townsend serves as CEO. The company has a scientific advisory board and a management team focused on research, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- LX2006 (Fabry Disease Cardiomyopathy): A gene therapy candidate in Phase 1/2 clinical trial for Fabry disease-related cardiomyopathy. The market is competitive with enzyme replacement therapies (ERTs) like Fabrazyme (Sanofi) and Galafold (Amicus Therapeutics), as well as other gene therapy developers. No confirmed market share or revenue at the moment due to development stage.
- LX1001 (Alzheimer's Disease): An AAV-based gene therapy candidate designed to deliver APOE2 to the brain for the treatment of Alzheimer's disease. Currently in early-stage development. Competition includes Biogen's Aduhelm, Eisai's Leqembi, and Eli Lilly's donanemab. No confirmed market share or revenue at the moment due to development stage.
Market Dynamics
Industry Overview
The gene therapy market is rapidly growing, driven by advancements in vector technology and increasing regulatory approvals. There is significant investment in gene therapy, with focus on rare diseases and oncology. The industry is facing challenges such as high manufacturing costs and complex regulatory pathways.
Positioning
Lexeo Therapeutics is focused on genetically defined diseases, a niche area within the broader gene therapy space. The company's platform and pipeline offer competitive advantage, but they face competition from larger pharmaceutical companies with greater resources.
Total Addressable Market (TAM)
The gene therapy market is estimated to reach multi-billion dollars in the coming years. Lexeo is targeting segments within this market by addressing genetically defined disorders, positioning themselves to capture a portion of this growing market.
Upturn SWOT Analysis
Strengths
- Targeted gene therapy approach for genetically defined diseases
- Experienced management team
- Strong intellectual property portfolio
- Advancing clinical programs
Weaknesses
- Early-stage clinical development carries high risk
- Limited commercial infrastructure
- Dependent on successful clinical trial outcomes
- Potential for manufacturing challenges
Opportunities
- Expansion of pipeline through new targets
- Partnerships with larger pharmaceutical companies
- Positive clinical trial results leading to accelerated approval
- Advancements in gene therapy delivery technologies
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles and changing guidelines
- Clinical trial failures
- High manufacturing costs
Competitors and Market Share
Key Competitors
- SNY (Sanofi)
- FOLD (Amicus Therapeutics)
- BIIB (Biogen)
- LLY (Eli Lilly)
Competitive Landscape
Lexeo competes with larger pharmaceutical companies in both the Fabry disease and Alzheimer's disease markets. Lexeo's advantage is its gene therapy approach. These are estimates and subject to fluctuation based on real-time data and product success.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is minimal as the company is focused on clinical development and has yet to commercialize any products.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst projections will be based on pipeline advancement and commercialization potential.
Recent Initiatives: Initiatives are centered around advancing LX2006 and LX1001 through clinical trials.
Summary
Lexeo Therapeutics is a promising clinical-stage gene therapy company targeting genetically defined diseases. Its success hinges on positive clinical trial outcomes for its lead candidates. While the company has a focused approach and strong IP, it faces significant competition and the inherent risks associated with drug development. Successful advancement of their pipeline is critical for long-term growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lexeo Therapeutics' website
- SEC filings
- Analyst reports
- Industry reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data are estimates based on current industry trends and are subject to change. Investing in biotechnology companies carries significant risks.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexeo Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2023-11-03 | CEO & Director Mr. R. Nolan Townsend | ||
Sector Healthcare | Industry Biotechnology | Full time employees 75 | Website https://www.lexeotx.com |
Full time employees 75 | Website https://www.lexeotx.com | ||
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company also develops LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has license agreement with Cornell University to conduct of the Phase 1/2 clinical trial of LX1001, as well as support the development of LX1004 program; research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.